To address these obstacles, STING-NPs were applied to synergize immune checkpoint blockade (e.g., anti-PD-1/anti-PD-L1, anti-CTL4) therapy, which reduced tumor growth, promoted long-term survival, and induced immunological memory [53, 59, 61]. Here, STING1 is linked to neoplasm.